

WHO's prequalification assessment fees

*WHO's prequalification assessment of
in vitro diagnostics*

© World Health Organization 2025

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

Suggested citation. WHO’s prequalification assessment fees: WHO’s prequalification assessment of in vitro diagnostics. Geneva: World Health Organization; 2025. <https://doi.org/10.2471/B09643>. Licence: [CC BY-NC-SA 3.0 IGO](https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Cataloguing-in-Publication (CIP) data. CIP data are available at <https://iris.who.int/>.

Sales, rights and licensing. To purchase WHO publications, see <https://www.who.int/publications/book-orders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

1. Introduction

This document (PQDx_299 version 3) has been prepared by the World Health Organization (WHO) to provide manufacturers with information on the fees associated with WHO's prequalification assessment for in vitro diagnostic medical devices (an "IVD" or "product"), and their payment. Effective 1 January 2026, the WHO Prequalification Programme will introduce an annual 10% increase on all applicable fees that have remained unchanged since 2017. This adjustment will apply for 2026 and 2027 (an additional 10% on the 2026 baseline). Thereafter, fees will be reviewed every two years. This document supersedes *"Prequalification fees - Prequalification of In Vitro Diagnostics. Version 2 Geneva: World Health Organization; 2018"*.

There are three types of fees associated with WHO's prequalification assessment process:

1. a prequalification assessment fee per product;
2. a change assessment fee per product; and
3. an annual fee per product.

These fees are non-refundable, and cover part of the cost incurred by WHO in connection with WHO's prequalification process.

The payment of any prequalification fees does not mean or imply any decision by WHO (whether positive or negative) on whether or not a product:

- will be accepted for WHO's prequalification assessment; or
- will be granted WHO prequalification listing; or
- will retain its prequalification listing status for any minimum duration.

For the avoidance of doubt, the fees associated with WHO's prequalification assessment process are separate and distinct from any fees, costs and expenses payable in connection with WHO's performance evaluation procedure. For more information about the latter, please refer to document PQDx_462 *"WHO's Performance evaluation fees"*.

2. WHO's prequalification assessment fee per product

A prequalification assessment fee is charged to, and payable by, the manufacturer once its application has been accepted by WHO—i.e., assuming that WHO determines that the product is eligible for WHO's prequalification assessment as described in the *"Overview of WHO's prequalification procedure for in vitro diagnostics"* document PQDx_007 (hereinafter, the "PQ Procedure").

If an application is accepted for WHO's prequalification assessment, then the following fee applies, subject to the planned increases and any adjustments resulting from periodic review as outlined in section 1 :

- for products undergoing a full prequalification assessment, as determined by WHO: US\$ 17 000 per product¹; or

¹ An application may only pertain to one product but may include several product configurations.

- for products undergoing an abridged prequalification assessment, as determined by WHO: US\$ 8 000 per product.

WHO will issue an invoice to the manufacturer to request payment of the applicable prequalification assessment fee. The manufacturer must pay the prequalification assessment fee as follows:

- fully in one instalment;
- by wire transfer of funds to WHO's bank account to be designated by WHO in writing as part of the invoice; and
- within 30 days from the date of WHO's invoice (unless another deadline communicated by WHO in the invoice).

The manufacturer must ensure that the prequalification assessment fee has been timely and fully paid, and must submit to WHO the electronic copies of proof of payment with the product dossier in accordance with WHO's instructions for uploading written proof of payment. WHO's prequalification assessment and/or any activities relating thereto will not commence or proceed, unless and until (among other things, see Section 6.4 of the PQ Procedure) the prequalification assessment fee has been fully paid by the manufacturer.

If the manufacturer fails to timely and fully pay the prequalification assessment fee, then the application will be terminated, and the product will not undergo WHO's prequalification assessment or be prequalified.

3. Change assessment fee per product

Assuming the product is included in WHO's list of prequalified IVDs, the manufacturer must promptly report to WHO in writing any post-prequalification changes (such as modifications to components, to manufacturing processes and/or to quality management systems).

Based on the change documentation submitted by the manufacturer to WHO, and on the type and level of assessment required in light of the post-prequalification change(s), WHO will determine in its discretion whether a change assessment fee applies.

If WHO determines that a change assessment fee applies, the amount of that fee is US\$ 3 000 per change request, subject to the planned increases and any adjustments resulting from periodic review as outlined in section 1.

WHO will issue an invoice to the manufacturer to request payment of the change assessment fee. The manufacturer must pay the change assessment fee as follows:

- fully in one instalment;
- by wire transfer of funds to WHO's bank account to be designated by WHO in writing as part of the invoice; and
- within 30 days from the date of WHO's invoice (unless another deadline is communicated by WHO in the invoice).

The manufacturer must ensure that all applicable change assessment fees have been timely and fully paid, and must submit to WHO the electronic copies of proof of payment in accordance with WHO's instructions for uploading written proof of payment. The change assessment and/or any activities relating thereto will not commence or proceed, unless and until the change assessment fee has been fully and timely paid by the manufacturer.

Failure to fully and timely pay the change assessment fees will result in WHO's rejection of the change request. In addition, the validity of the product's prequalification status is subject to and dependent upon the manufacturer's fulfilment, within the applicable deadlines, of all post-qualification obligations and requirements described in Section 12 of the PQ Procedure. Failure or delay to comply with all post-qualification obligations and requirements will result in the suspension or delisting of the product from WHO's list of prequalified IVDs, as determined by WHO pursuant to and in accordance with the PQ Procedure.

4. Annual fee per product

An annual fee is levied for each product listed on WHO's list of prequalified in vitro diagnostics that, as of 1 September of any given year, has been listed on WHO's list of prequalified in vitro diagnostics for 12 months or more.

If WHO determines that an annual fee applies, then the amount of the annual fee is US \$4 000 per product, subject to the planned increases and any adjustments resulting from periodic review as outlined in section 1.

WHO will issue an invoice to the manufacturer on or before 1 October of each applicable year to request payment of the annual fee. The manufacturer must pay the annual fee as follows:

- fully in one instalment;
- by wire transfer of funds to WHO's bank account to be designated by WHO in writing as part of the invoice; and
- before 30 November of the calendar year in which the invoice is issued, unless another deadline is stated in WHO's invoice.

The manufacturer must ensure that all applicable annual fees have been fully and timely paid and must submit to WHO the electronic copies of proof of payment in accordance with WHO's instructions for uploading written proof of payment before 31 December of the calendar year in which the invoice is issued.

Failure to fully and timely pay the annual fee(s) will result in the suspension or delisting of the product from WHO's list of prequalified IVDs, as determined by WHO in its discretion pursuant to and in accordance with the PQ Procedure, including Section 12 thereof.

Payment of the annual fee does not, however, mean or imply that the prequalified product will not, for other reasons, be removed or suspended from WHO's list of prequalified IVDs pursuant to and in accordance with the terms of the PQ Procedure.

5. Date of effect

This fees, terms and conditions of this document apply with immediate effect.

6. Contact information

Any inquiries regarding WHO's prequalification assessment of IVDs should be addressed to: diagnostics@who.int